Can a calming drug tame the deadly stress of sepsis?
NCT ID NCT07470775
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving the sedative dexmedetomidine early to adults with septic shock can calm their overactive nervous system and improve survival. 168 participants will receive either the drug or a placebo for 48 hours, with close monitoring of heart function, inflammation, and organ health. The goal is to see if this approach reduces organ damage and the need for strong blood pressure medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dexmedetomidine (a sedative drug that calms the nervous system)
What this could lead to
If it works, this could point toward a way to reduce organ damage and improve survival in septic shock by calming the body's overactive stress response.
What could go wrong
This is a relatively small, early-phase trial (168 people) testing a drug already used for sedation, so the benefit may be modest or not confirmed in larger studies. Risks include bradycardia (slow heart rate) and low blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••